Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Correction to Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-Negative Bacteria.

Gerasyuto AI, Arnold MA, Wang J, Chen G, Zhang X, Smith S, Woll MG, Baird J, Zhang N, Almstead NG, Narasimhan J, Peddi S, Dumble M, Sheedy J, Weetall M, Branstrom AA, Prasad JVN, Karp GM.

J Med Chem. 2018 Oct 25;61(20):9394. doi: 10.1021/acs.jmedchem.8b01538. Epub 2018 Oct 16. No abstract available.

2.

Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.

Gerasyuto AI, Arnold MA, Wang J, Chen G, Zhang X, Smith S, Woll MG, Baird J, Zhang N, Almstead NG, Narasimhan J, Peddi S, Dumble M, Sheedy J, Weetall M, Branstrom AA, Prasad JVN, Karp GM.

J Med Chem. 2018 May 24;61(10):4456-4475. doi: 10.1021/acs.jmedchem.8b00114. Epub 2018 May 14. Erratum in: J Med Chem. 2018 Oct 25;61(20):9394.

3.

Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.

Dey A, Xiong X, Crim A, Dwivedi SKD, Mustafi SB, Mukherjee P, Cao L, Sydorenko N, Baiazitov R, Moon YC, Dumble M, Davis T, Bhattacharya R.

Mol Cancer Ther. 2018 Jan;17(1):39-49. doi: 10.1158/1535-7163.MCT-17-0574. Epub 2017 Nov 20.

PMID:
29158468
4.

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.

Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K.

Blood Cancer J. 2017 Feb 17;7(2):e527. doi: 10.1038/bcj.2017.8.

5.

Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.

Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, Kumar R.

PLoS One. 2014 Jun 30;9(6):e100880. doi: 10.1371/journal.pone.0100880. eCollection 2014.

6.

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.

Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.

Mol Cancer Ther. 2011 Dec;10(12):2309-19. doi: 10.1158/1535-7163.MCT-11-0329. Epub 2011 Oct 25.

7.

Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models.

Terzian T, Dumble M, Arbab F, Thaller C, Donehower LA, Lozano G, Justice MJ, Roop DR, Box NF.

J Pathol. 2011 Aug;224(4):540-52. doi: 10.1002/path.2891. Epub 2011 Jun 14.

8.

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID.

Angiogenesis. 2011 Sep;14(3):245-53. doi: 10.1007/s10456-011-9209-1. Epub 2011 Mar 31.

9.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.

Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP, Scherzer D, Shu A, Bobko MA, Chadderton AR, Dumble M, Gardiner CM, Gilbert S, Liu Q, Rabindran SK, Sudakin V, Xiang H, Brady PG, Campobasso N, Ward P, Axten JM.

J Med Chem. 2011 Mar 24;54(6):1871-95. doi: 10.1021/jm101527u. Epub 2011 Feb 22.

PMID:
21341675
10.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK.

Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.

11.

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.

Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, Kruger RG, Gontarek RR, Maksimchuk KR, Suravajjala S, Lapierre RR, Shotwell JB, Wilson JW, Chamberlain SD, Rabindran SK, Kumar R.

Mol Cancer Ther. 2009 Oct;8(10):2811-20. doi: 10.1158/1535-7163.MCT-09-0423.

12.

Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.

Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C, Dumble M, Yang J, Anderson K, Wilson BJ, Emmitte KA, Rabindran SK, Kumar R.

Clin Cancer Res. 2009 May 1;15(9):3058-67. doi: 10.1158/1078-0432.CCR-08-2530. Epub 2009 Apr 21.

13.

Altered mammary gland development in the p53+/m mouse, a model of accelerated aging.

Gatza CE, Dumble M, Kittrell F, Edwards DG, Dearth RK, Lee AV, Xu J, Medina D, Donehower LA.

Dev Biol. 2008 Jan 1;313(1):130-41. Epub 2007 Oct 12.

14.

Tumor suppressor dosage regulates stem cell dynamics during aging.

Gatza C, Moore L, Dumble M, Donehower LA.

Cell Cycle. 2007 Jan 1;6(1):52-5. Epub 2007 Jan 4. Review.

PMID:
17245110
15.

The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging.

Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, Donehower LA.

Blood. 2007 Feb 15;109(4):1736-42. Epub 2006 Oct 10.

16.

Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.

Nannenga B, Lu X, Dumble M, Van Maanen M, Nguyen TA, Sutton R, Kumar TR, Donehower LA.

Mol Carcinog. 2006 Aug;45(8):594-604.

PMID:
16652371
17.

Insights into aging obtained from p53 mutant mouse models.

Dumble M, Gatza C, Tyner S, Venkatachalam S, Donehower LA.

Ann N Y Acad Sci. 2004 Jun;1019:171-7. Review.

PMID:
15247009
18.

Generation and characterization of p53 mutant mice.

Dumble ML, Donehower LA, Lu X.

Methods Mol Biol. 2003;234:29-49.

PMID:
12824523
19.
20.

A modified choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse liver.

Akhurst B, Croager EJ, Farley-Roche CA, Ong JK, Dumble ML, Knight B, Yeoh GC.

Hepatology. 2001 Sep;34(3):519-22.

PMID:
11526537
21.

Supplemental Content

Loading ...
Support Center